Data Sheet (Cat.No.T8616)

TargetMol

Fasentin

Chemical Properties



CAS No. : 392721-37-8

Formula: C11H9ClF3NO2

Molecular Weight: 279.64

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Fasentin (N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide) is an inhibitor of GluT1.
Targets(IC50)	Apoptosis,TNF,transporter
In vitro	Fasentin has been described as a modulator of GLUT-1 and GLUT-4 transporters, thus inhibiting glucose uptake in some cancer cells.

Solubility Information

Solubility	DMSO: 257.5 mg/mL (920.83 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.15 mM),Sonication is recommended. 10% DMSO+90% Saline: 10 mg/mL (35.76 mM),Suspension. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.576 mL	17.8801 mL	35.7603 mL
5 mM	0.7152 mL	3.576 mL	7.1521 mL
10 mM	0.3576 mL	1.788 mL	3.576 mL
50 mM	0.0715 mL	0.3576 mL	0.7152 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ocaa M C , Beatriz Martínez-Poveda, Manuel Marí-Beffa, et al. Fasentin diminishes endothelial cell proliferation, differentiation and invasion in a glucose metabolism-independent manner[J]. entific Reports, 2020, 10(1).
Kraus, Dominik, Reckenbeil, et al. Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation[J]. Cellular Oncology, 2018.